DR. REDDY'S LABORATORIES-ADR (RDY) Fundamental Analysis & Valuation
NYSE:RDY • US2561352038
Current stock price
13.32 USD
-0.15 (-1.11%)
At close:
13.32 USD
0 (0%)
After Hours:
This RDY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. RDY Profitability Analysis
1.1 Basic Checks
- In the past year RDY was profitable.
- RDY had a positive operating cash flow in the past year.
- RDY had positive earnings in each of the past 5 years.
- Each year in the past 5 years RDY had a positive operating cash flow.
1.2 Ratios
- The Return On Assets of RDY (10.62%) is better than 92.19% of its industry peers.
- With an excellent Return On Equity value of 16.03%, RDY belongs to the best of the industry, outperforming 89.06% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 13.03%, RDY belongs to the top of the industry, outperforming 91.67% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for RDY is above the industry average of 13.06%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.62% | ||
| ROE | 16.03% | ||
| ROIC | 13.03% |
ROA(3y)13.25%
ROA(5y)10.88%
ROE(3y)18.65%
ROE(5y)15.68%
ROIC(3y)15.26%
ROIC(5y)13.95%
1.3 Margins
- RDY has a better Profit Margin (16.82%) than 89.06% of its industry peers.
- RDY's Profit Margin has improved in the last couple of years.
- Looking at the Operating Margin, with a value of 19.62%, RDY belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
- In the last couple of years the Operating Margin of RDY has grown nicely.
- With a decent Gross Margin value of 66.88%, RDY is doing good in the industry, outperforming 75.52% of the companies in the same industry.
- In the last couple of years the Gross Margin of RDY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.62% | ||
| PM (TTM) | 16.82% | ||
| GM | 66.88% |
OM growth 3Y9.42%
OM growth 5Y4.7%
PM growth 3Y19.59%
PM growth 5Y8.42%
GM growth 3Y2.12%
GM growth 5Y0.39%
2. RDY Health Analysis
2.1 Basic Checks
- RDY has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- RDY has about the same amout of shares outstanding than it did 1 year ago.
- RDY has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, RDY has a worse debt to assets ratio.
2.2 Solvency
- RDY has an Altman-Z score of 5.67. This indicates that RDY is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 5.67, RDY is in the better half of the industry, outperforming 78.65% of the companies in the same industry.
- RDY has a debt to FCF ratio of 3.17. This is a good value and a sign of high solvency as RDY would need 3.17 years to pay back of all of its debts.
- RDY has a better Debt to FCF ratio (3.17) than 89.58% of its industry peers.
- RDY has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
- RDY has a Debt to Equity ratio (0.03) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 3.17 | ||
| Altman-Z | 5.67 |
ROIC/WACC1.29
WACC10.13%
2.3 Liquidity
- A Current Ratio of 1.85 indicates that RDY should not have too much problems paying its short term obligations.
- RDY's Current ratio of 1.85 is on the low side compared to the rest of the industry. RDY is outperformed by 64.58% of its industry peers.
- RDY has a Quick Ratio of 1.35. This is a normal value and indicates that RDY is financially healthy and should not expect problems in meeting its short term obligations.
- RDY's Quick ratio of 1.35 is on the low side compared to the rest of the industry. RDY is outperformed by 68.23% of its industry peers.
- RDY does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.35 |
3. RDY Growth Analysis
3.1 Past
- RDY shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.81%.
- The Earnings Per Share has been growing by 23.62% on average over the past years. This is a very strong growth
- RDY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.06%.
- RDY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.26% yearly.
EPS 1Y (TTM)3.81%
EPS 3Y33.55%
EPS 5Y23.62%
EPS Q2Q%-14.29%
Revenue 1Y (TTM)11.06%
Revenue growth 3Y14.86%
Revenue growth 5Y13.26%
Sales Q2Q%4.44%
3.2 Future
- The Earnings Per Share is expected to decrease by -1.22% on average over the next years.
- RDY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.56% yearly.
EPS Next Y-7.04%
EPS Next 2Y-8.78%
EPS Next 3Y-1.22%
EPS Next 5YN/A
Revenue Next Year6.48%
Revenue Next 2Y4.7%
Revenue Next 3Y6.26%
Revenue Next 5Y6.56%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. RDY Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 18.50, the valuation of RDY can be described as rather expensive.
- 83.33% of the companies in the same industry are more expensive than RDY, based on the Price/Earnings ratio.
- When comparing the Price/Earnings ratio of RDY to the average of the S&P500 Index (25.60), we can say RDY is valued slightly cheaper.
- A Price/Forward Earnings ratio of 22.04 indicates a rather expensive valuation of RDY.
- Based on the Price/Forward Earnings ratio, RDY is valued a bit cheaper than 76.56% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 22.84. RDY is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.5 | ||
| Fwd PE | 22.04 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, RDY is valued cheaply inside the industry as 85.42% of the companies are valued more expensively.
- 76.04% of the companies in the same industry are more expensive than RDY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 56.09 | ||
| EV/EBITDA | 11.21 |
4.3 Compensation for Growth
- The excellent profitability rating of RDY may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.78
EPS Next 2Y-8.78%
EPS Next 3Y-1.22%
5. RDY Dividend Analysis
5.1 Amount
- With a yearly dividend of 0.61%, RDY is not a good candidate for dividend investing.
- RDY's Dividend Yield is rather good when compared to the industry average which is at 0.68. RDY pays more dividend than 89.06% of the companies in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.88, RDY's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.61% |
5.2 History
- The dividend of RDY decreases each year by -19.44%.
- RDY has been paying a dividend for at least 10 years, so it has a reliable track record.
Dividend Growth(5Y)-19.44%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
- RDY pays out 11.54% of its income as dividend. This is a sustainable payout ratio.
- RDY's earnings and Dividend Rate are declining. This means the current dividend is most likely not sustainable.
DP11.54%
EPS Next 2Y-8.78%
EPS Next 3Y-1.22%
RDY Fundamentals: All Metrics, Ratios and Statistics
13.32
-0.15 (-1.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-21 2026-01-21/amc
Earnings (Next)05-07 2026-05-07/amc
Inst Owners52.01%
Inst Owner Change0.3%
Ins Owners1.23%
Ins Owner Change0%
Market Cap11.09B
Revenue(TTM)346.82B
Net Income(TTM)57.72B
Analysts67.27
Price Target15.24 (14.41%)
Short Float %2.34%
Short Ratio6.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.61% |
Yearly Dividend0.08
Dividend Growth(5Y)-19.44%
DP11.54%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.63%
Min EPS beat(2)-8.52%
Max EPS beat(2)-6.74%
EPS beat(4)1
Avg EPS beat(4)-3.93%
Min EPS beat(4)-8.52%
Max EPS beat(4)2.77%
EPS beat(8)4
Avg EPS beat(8)-0.94%
EPS beat(12)8
Avg EPS beat(12)6.66%
EPS beat(16)10
Avg EPS beat(16)7.01%
Revenue beat(2)0
Avg Revenue beat(2)-2.69%
Min Revenue beat(2)-3.88%
Max Revenue beat(2)-1.51%
Revenue beat(4)1
Avg Revenue beat(4)-1.2%
Min Revenue beat(4)-3.88%
Max Revenue beat(4)1%
Revenue beat(8)4
Avg Revenue beat(8)0.25%
Revenue beat(12)7
Avg Revenue beat(12)1.24%
Revenue beat(16)9
Avg Revenue beat(16)1.2%
PT rev (1m)0%
PT rev (3m)2.13%
EPS NQ rev (1m)0.02%
EPS NQ rev (3m)-3.66%
EPS NY rev (1m)-0.75%
EPS NY rev (3m)-0.94%
Revenue NQ rev (1m)-0.43%
Revenue NQ rev (3m)-1.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.5 | ||
| Fwd PE | 22.04 | ||
| P/S | 3.02 | ||
| P/FCF | 56.09 | ||
| P/OCF | 17.61 | ||
| P/B | 2.88 | ||
| P/tB | 4.23 | ||
| EV/EBITDA | 11.21 |
EPS(TTM)0.72
EY5.41%
EPS(NY)0.6
Fwd EY4.54%
FCF(TTM)0.24
FCFY1.78%
OCF(TTM)0.76
OCFY5.68%
SpS4.41
BVpS4.63
TBVpS3.15
PEG (NY)N/A
PEG (5Y)0.78
Graham Number8.66
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.62% | ||
| ROE | 16.03% | ||
| ROCE | 17.14% | ||
| ROIC | 13.03% | ||
| ROICexc | 16.05% | ||
| ROICexgc | 25.11% | ||
| OM | 19.62% | ||
| PM (TTM) | 16.82% | ||
| GM | 66.88% | ||
| FCFM | 5.38% |
ROA(3y)13.25%
ROA(5y)10.88%
ROE(3y)18.65%
ROE(5y)15.68%
ROIC(3y)15.26%
ROIC(5y)13.95%
ROICexc(3y)19.62%
ROICexc(5y)17.62%
ROICexgc(3y)25.36%
ROICexgc(5y)22.59%
ROCE(3y)21.22%
ROCE(5y)19.86%
ROICexgc growth 3Y6.58%
ROICexgc growth 5Y2.58%
ROICexc growth 3Y0.6%
ROICexc growth 5Y-0.12%
OM growth 3Y9.42%
OM growth 5Y4.7%
PM growth 3Y19.59%
PM growth 5Y8.42%
GM growth 3Y2.12%
GM growth 5Y0.39%
F-Score4
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 3.17 | ||
| Debt/EBITDA | 0.13 | ||
| Cap/Depr | 211.61% | ||
| Cap/Sales | 11.76% | ||
| Interest Coverage | 16.55 | ||
| Cash Conversion | 68.09% | ||
| Profit Quality | 32% | ||
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 5.67 |
F-Score4
WACC10.13%
ROIC/WACC1.29
Cap/Depr(3y)179.81%
Cap/Depr(5y)161.03%
Cap/Sales(3y)9.33%
Cap/Sales(5y)8.68%
Profit Quality(3y)47.43%
Profit Quality(5y)60.48%
High Growth Momentum
Growth
EPS 1Y (TTM)3.81%
EPS 3Y33.55%
EPS 5Y23.62%
EPS Q2Q%-14.29%
EPS Next Y-7.04%
EPS Next 2Y-8.78%
EPS Next 3Y-1.22%
EPS Next 5YN/A
Revenue 1Y (TTM)11.06%
Revenue growth 3Y14.86%
Revenue growth 5Y13.26%
Sales Q2Q%4.44%
Revenue Next Year6.48%
Revenue Next 2Y4.7%
Revenue Next 3Y6.26%
Revenue Next 5Y6.56%
EBIT growth 1Y1.53%
EBIT growth 3Y25.68%
EBIT growth 5Y18.58%
EBIT Next Year11.9%
EBIT Next 3Y6.94%
EBIT Next 5Y9.33%
FCF growth 1Y-62.42%
FCF growth 3Y9.92%
FCF growth 5Y-12.7%
OCF growth 1Y-18.43%
OCF growth 3Y18.21%
OCF growth 5Y9.24%
DR. REDDY'S LABORATORIES-ADR / RDY Fundamental Analysis FAQ
What is the ChartMill fundamental rating of DR. REDDY'S LABORATORIES-ADR (RDY) stock?
ChartMill assigns a fundamental rating of 6 / 10 to RDY.
What is the valuation status for RDY stock?
ChartMill assigns a valuation rating of 5 / 10 to DR. REDDY'S LABORATORIES-ADR (RDY). This can be considered as Fairly Valued.
How profitable is DR. REDDY'S LABORATORIES-ADR (RDY) stock?
DR. REDDY'S LABORATORIES-ADR (RDY) has a profitability rating of 8 / 10.
What are the PE and PB ratios of DR. REDDY'S LABORATORIES-ADR (RDY) stock?
The Price/Earnings (PE) ratio for DR. REDDY'S LABORATORIES-ADR (RDY) is 18.5 and the Price/Book (PB) ratio is 2.88.
How financially healthy is DR. REDDY'S LABORATORIES-ADR?
The financial health rating of DR. REDDY'S LABORATORIES-ADR (RDY) is 6 / 10.